AU2004228008B2 - Tumor-targeting drug-loaded particles - Google Patents

Tumor-targeting drug-loaded particles Download PDF

Info

Publication number
AU2004228008B2
AU2004228008B2 AU2004228008A AU2004228008A AU2004228008B2 AU 2004228008 B2 AU2004228008 B2 AU 2004228008B2 AU 2004228008 A AU2004228008 A AU 2004228008A AU 2004228008 A AU2004228008 A AU 2004228008A AU 2004228008 B2 AU2004228008 B2 AU 2004228008B2
Authority
AU
Australia
Prior art keywords
tumor
microparticles
paclitaxel
therapeutic agent
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004228008A
Other languages
English (en)
Other versions
AU2004228008A1 (en
Inventor
Jessie L.-S. Au
M. Guillaume Wientjes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2004228008A1 publication Critical patent/AU2004228008A1/en
Application granted granted Critical
Publication of AU2004228008B2 publication Critical patent/AU2004228008B2/en
Priority to AU2009200463A priority Critical patent/AU2009200463B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
AU2004228008A 2003-04-03 2004-04-02 Tumor-targeting drug-loaded particles Ceased AU2004228008B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2009200463A AU2009200463B2 (en) 2003-04-03 2009-02-06 Tumor-Targeting Drug Loaded Particles

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46082703P 2003-04-03 2003-04-03
US60/460,827 2003-04-03
PCT/US2004/010230 WO2004089291A2 (en) 2003-04-03 2004-04-02 Tumor-targeting drug-loaded particles

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2009200463A Division AU2009200463B2 (en) 2003-04-03 2009-02-06 Tumor-Targeting Drug Loaded Particles

Publications (2)

Publication Number Publication Date
AU2004228008A1 AU2004228008A1 (en) 2004-10-21
AU2004228008B2 true AU2004228008B2 (en) 2008-11-06

Family

ID=33159807

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004228008A Ceased AU2004228008B2 (en) 2003-04-03 2004-04-02 Tumor-targeting drug-loaded particles

Country Status (8)

Country Link
EP (1) EP1608359A4 (ko)
JP (1) JP4927535B2 (ko)
KR (1) KR100849911B1 (ko)
CN (2) CN102697737B (ko)
AU (1) AU2004228008B2 (ko)
CA (1) CA2520475C (ko)
IL (1) IL171185A (ko)
WO (1) WO2004089291A2 (ko)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005084710A2 (en) * 2004-03-02 2005-09-15 Massachusetts Institute Of Technology Nanocell drug delivery system
DK1865924T3 (en) * 2005-03-31 2016-02-29 Lidds Ab Method of treating prostate diseases based on local administration of active substances
BRPI0600285C1 (pt) * 2006-01-13 2011-10-11 Brz Biotecnologia Ltda compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas
JP2007277217A (ja) * 2006-03-17 2007-10-25 Fujifilm Corp 薬剤を均一に封入した生分解性マトリックス
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
EP2066321A2 (en) * 2006-11-20 2009-06-10 Lutonix, Inc. Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
EP2074988B1 (en) 2007-12-28 2018-03-14 Industrial Technology Research Institute Sustained release composition and manufacturing method thereof
US9161943B2 (en) 2007-12-31 2015-10-20 Industrial Technology Research Institute Sustained release composition and manufacturing method thereof
WO2009116556A1 (ja) * 2008-03-19 2009-09-24 富士フイルム株式会社 注射用医薬組成物
EP2309991B1 (en) 2008-06-16 2019-03-06 Pfizer Inc Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
PL2774608T3 (pl) 2008-06-16 2020-05-18 Pfizer Inc. Polimerowe nanocząstki napełnione lekiem oraz sposoby ich wytwarzania i zastosowania
WO2010005726A2 (en) 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
US8563041B2 (en) 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
US20100216804A1 (en) 2008-12-15 2010-08-26 Zale Stephen E Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents
CN102811743B (zh) 2009-12-11 2015-11-25 佰恩德治疗股份有限公司 冻干治疗颗粒的稳定制剂
WO2011084513A2 (en) 2009-12-15 2011-07-14 Bind Biosciences, Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
KR101314579B1 (ko) * 2011-04-07 2013-10-10 광주과학기술원 파크리탁셀이 선적된 고분자 나노입자 및 그 제조방법
JP2013053103A (ja) * 2011-09-05 2013-03-21 Ltt Bio-Pharma Co Ltd 薬物を封入した肝臓集積性ナノ粒子
WO2013124867A1 (en) * 2012-02-21 2013-08-29 Amrita Vishwa Vidyapeetham University Polymer - polymer or polymer - protein core - shell nano medicine loaded with multiple drug molecules
TR201909389T4 (tr) 2012-09-17 2019-07-22 Pfizer Terapötik nanopartikülleri hazırlamaya yönelik proses.
US10143700B2 (en) 2013-02-19 2018-12-04 Amrita Vishwa Vidyapeetham Nanoparticle formulations for delivering multiple therapeutic agents
EP3046584B1 (en) 2013-09-16 2017-07-19 AstraZeneca AB Therapeutic polymeric nanoparticles and methods of making and using same
MX2016012009A (es) 2014-03-14 2016-12-05 Pfizer Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso.
CN107205939B (zh) * 2015-01-05 2020-11-06 波士顿科学国际有限公司 用于实体瘤治疗的可生物降解的药物洗脱微球
DK3302431T3 (da) 2015-06-04 2020-11-30 Crititech Inc Taxanpartikler og anvendelse deraf
WO2017083717A1 (en) * 2015-11-11 2017-05-18 Qrono, Inc. Sustained release pharmaceutical compositions and methods of use
CA3018989A1 (en) 2016-04-04 2017-10-12 Crititech, Inc. Methods for solid tumor treatment
CN106075535B (zh) * 2016-06-14 2019-04-02 武汉纺织大学 一种医用敷料及其制备方法
WO2018011040A1 (en) * 2016-07-13 2018-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Plga microparticles loaded with a fluoroquinolone for the treatment of respiratory diseases
US10993919B2 (en) 2016-10-04 2021-05-04 University Of Florida Research Foundation, Inc. Chondroprotective nanoparticles for the treatment of osteoarthritis
CN107049984A (zh) * 2017-03-14 2017-08-18 武汉理工大学 一种载紫杉醇聚乳酸‑羟基乙酸微球的制备方法
KR102024273B1 (ko) * 2017-03-27 2019-11-04 주식회사 피에프디 약물 작용 관리 장치 및 방법
JP2020523285A (ja) 2017-06-09 2020-08-06 クリチテック，インコーポレイテッド 抗腫瘍粒子の嚢胞内注入による上皮嚢胞の治療
JP6840869B2 (ja) 2017-06-14 2021-03-10 クリチテック，インコーポレイテッド 肺障害の治療方法
EP3691631A1 (en) 2017-10-03 2020-08-12 Crititech, Inc. Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
JP2021509663A (ja) * 2018-01-05 2021-04-01 クリティテック・インコーポレイテッド タキサン粒子の局所投与による膀胱癌の治療
GB201800912D0 (en) * 2018-01-19 2018-03-07 Ucl Business Plc Compositions for the treatment of a disease of the urinary tract and treatment of a disease involving the intracellular delivery of the particle
WO2019231499A1 (en) * 2018-05-31 2019-12-05 Crititech, Inc. Use of antineoplastic agents to stimulate the immune system for treatment of cancer
WO2020072090A1 (en) * 2018-10-03 2020-04-09 Crititech, Inc. Use of antineoplastic agents to stimulate the immune system for production of tertiary lymphoid structures (tls)
EP3750524A1 (en) * 2019-06-13 2020-12-16 CAPNOMED GmbH Delayed and sustained delivery of anticancer drugs
EP3750523A1 (en) * 2019-06-13 2020-12-16 CAPNOMED GmbH Active substance delivery system
JPWO2022075318A1 (ko) * 2020-10-08 2022-04-14
US20240016774A1 (en) * 2020-10-14 2024-01-18 Foundry Therapeutics, Inc. Implantable depots for localized, sustained, controlled release of therapeutic agents to treat cancer and related conditions
WO2022187839A1 (en) * 2021-03-05 2022-09-09 H. Lee Moffitt Cancer Center And Research Institute Inc. Combination therapy to treat temperature senstive mutant tumors
CN115770224B (zh) * 2023-01-17 2023-04-18 中国人民解放军总医院第一医学中心 一种携载紫杉醇药物的丙烯酸微球及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US20020164374A1 (en) * 1997-10-29 2002-11-07 John Jackson Polymeric systems for drug delivery and uses thereof
JP2003524624A (ja) * 1999-04-09 2003-08-19 ジェシー エル エス オウ 治療薬の組織への送達を高める方法及び組成物
US6287588B1 (en) * 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
US6444227B1 (en) * 1999-08-05 2002-09-03 Roche Vitamins Inc. Process for preparing fat soluble beadlets
DE60128261T3 (de) * 2000-12-21 2016-06-30 Alrise Biosystems Gmbh Verfahren umfassend einen induzierten phasenübergang zur herstellung von hydrophobe wirkstoffe enthaltenden mikropartikeln
JP2004529934A (ja) * 2001-05-01 2004-09-30 アンジオテック ファーマシューティカルズ，インコーポレイテッド 抗微小管剤およびポリペプチドまたはポリサッカリドを含む組成物、ならびに炎症状態を処置するための医薬品の調製のためのそれらの組成物の使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Au, J et al. Cancer Research 58: 2141-2148 (1998) *

Also Published As

Publication number Publication date
AU2009200463A1 (en) 2009-03-05
CN102697737A (zh) 2012-10-03
EP1608359A2 (en) 2005-12-28
JP4927535B2 (ja) 2012-05-09
CN1816331A (zh) 2006-08-09
KR20060006911A (ko) 2006-01-20
CA2520475A1 (en) 2004-10-21
KR100849911B1 (ko) 2008-08-04
IL171185A (en) 2013-07-31
EP1608359A4 (en) 2011-08-17
WO2004089291A3 (en) 2005-04-21
CA2520475C (en) 2012-10-09
WO2004089291A2 (en) 2004-10-21
CN1816331B (zh) 2012-08-08
AU2004228008A1 (en) 2004-10-21
CN102697737B (zh) 2014-03-19
JP2006522148A (ja) 2006-09-28

Similar Documents

Publication Publication Date Title
AU2004228008B2 (en) Tumor-targeting drug-loaded particles
US8043631B2 (en) Tumor targeting drug-loaded particles
Tan et al. Doxorubicin delivery systems based on chitosan for cancer therapy
Sinha et al. Chitosan microspheres as a potential carrier for drugs
Tang et al. Co-delivery of docetaxel and Poloxamer 235 by PLGA–TPGS nanoparticles for breast cancer treatment
Wu et al. Genistein-loaded nanoparticles of star-shaped diblock copolymer mannitol-core PLGA–TPGS for the treatment of liver cancer
Cao et al. Dual drug release from core–shell nanoparticles with distinct release profiles
Wathoni et al. Enteric-coated strategies in colorectal cancer nanoparticle drug delivery system
Guo et al. Direct site-specific treatment of skin cancer using doxorubicin-loaded nanofibrous membranes
JP2014518862A (ja) 薬物送達用ポリマーナノ粒子
Haggag et al. Nanoencapsulation of sophorolipids in PEGylated poly (lactide-co-glycolide) as a novel approach to target colon carcinoma in the murine model
Xu et al. Polysaccharide-based nanoparticles for co-loading mitoxantrone and verapamil to overcome multidrug resistance in breast tumor
Taghavi et al. Synthesis of chimeric polymersomes based on PLA-b-PHPMA and PCL-b-PHPMA for nucleoline guided delivery of SN38
Liang et al. Development of rifapentine-loaded PLGA-based nanoparticles: in vitro characterisation and in vivo study in mice
CN112826939A (zh) 一种腹腔灌注纳米药物及其制备方法与应用
Schaefer et al. Effect of tricaprin on the physical characteristics and in vitro release of etoposide from PLGA microspheres
Froiio et al. Polymer-based nanocontainers for drug delivery
WO2017084522A1 (zh) 一种新型抗癌药物纳米制剂及其制备方法
US20120121510A1 (en) Localized therapy following breast cancer surgery
Jin et al. Cellular uptake and radiosensitization of SR-2508 loaded PLGA nanoparticles
CN101181273A (zh) 壳聚糖-聚天冬氨酸-5氟尿嘧啶纳米粒子的制备方法
CN1927183B (zh) 抗肿瘤药物表阿霉素缓释微球制剂及制备方法
Singh et al. Cubosomes: An Emerging and Promising Drug Delivery System for Enhancing Cancer Therapy
Tazhbayev et al. Nanoparticles on the basis of polylactic acid and polylactic-co-glycolic acids loaded with drugs
US20220323368A1 (en) Active substance delivery system with delayed delivery

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired